buy pipelin on-track pt lower
base updat gist market size estim
messag report financi result pipelin updat
larg within investor expect phase trial intrigu remain on-track
complet enrol around time also expect provid
updat clinical-stag asset includ ripretinib beyond gist inhibitor
inhibitor rebastinib submit ind autophagi inhibitor
updat analysi us payor claim data howev point
moder lower total address market ripretinib gist
reduc long-term revenu forecast maintain buy reduc pt
address patient popul gist analyz us payor claim data
believ approxim treatment-elig patient
gist approxim patient remain elig upon progress onto
subsequ line therapi gist gist new estim
meaning reduc prior company-provid estim patient
gist gist addit convers management call
compani highlight estim annual gist incid eu jpn
metastat expect similar patient drop-off rate subsequ
line therapi
phase trial intrigu remain on-track complet enrol recal
intrigu pivot phase trial evalu ripretinib vs sutent gist
compani increas trial enrol see prior note due higher-
than-expect number censor patient driven factor discontinu
local progress without central confirm consent withdraw patient never
receiv therapi random management emphas intrigu remain on-track
complet enrol chang number event
requir trigger analysi statist plan
clinic pipelin updat beyond ripretinib gist system mastocytosi
rebastinib link remain on-track throughout
compani remain on-track execut phase ripretinib trial expect read
updat least one cohort gist inhibitor
remain on-track updat select updat phase data tenosynovi giant
cell tumor tgct rebastinib read phase ib/ii combin data
carboplatin paclitaxel autophagi ulk kinas inhibitor remain
on-track file ind
updat estim account result maintain buy reduc pt
pt previous end cash cash equival
exclud proce recent financ see compani
expect provid runway modestli adjust oper expens
forecast account result well moder decreas long-term revenu
forecast given potenti smaller-than-previ expect address gist
patient popul new pt maintain buy rate
page analyst certif import disclosur
valuat risk
price target per share previous base probability-adjust sale estim gist
net cash balanc sheet year use discount cash flow analysi use wacc termin
growth rate appli termin year post-assum gener entri
risk rate valuat includ regulatori commerci setback potenti emerg new
competitor lower product sale expect cash flow-neg compani may also engag financ activ
dilut exist sharehold
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
page analyst certif import disclosur
